Related Experiment Videos
ABT-773: a new ketolide antibiotic
1Bristol-Myers Squibb Pharmaceutical Research Institute, Department of Microbiology, 5 Research Parkway, Wallingford, CT 06492, USA.
Expert Opinion on Investigational Drugs
|February 15, 2001
Summary
ABT-773, a novel ketolide antibacterial, shows broad-spectrum efficacy against resistant bacteria. This new erythromycin derivative is being developed for respiratory infections, demonstrating improved activity against resistant Streptococcus pneumoniae strains.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- ABT-773 is a semisynthetic derivative of erythromycin A, belonging to the ketolide class of broad-spectrum antibacterial agents.
- Ketolides are being developed to address increasing bacterial resistance to existing antibiotics.
Purpose of the Study:
- To evaluate the antibacterial spectrum and activity of ABT-773, particularly against resistant strains.
- To assess the potential of ABT-773 as a respiratory agent.
Main Methods:
- In vitro susceptibility testing against a panel of Gram-positive, Gram-negative, and intracellular bacteria.
- Evaluation of activity against macrolide-resistant Streptococcus pneumoniae and MLS(B)-constitutive expressing streptococci.
Main Results:
- ABT-773 exhibits broad-spectrum activity, including against Gram-positive and some Gram-negative organisms.
- Demonstrated expanded in vitro activity against macrolide-resistant Streptococcus pneumoniae.
- Showed improved activity against streptococci expressing MLS(B) constitutive resistance.
Conclusions:
- ABT-773 possesses promising broad-spectrum antibacterial properties.
- Its structural modifications enhance activity against key resistant pathogens.
- ABT-773 is a potential candidate for treating respiratory tract infections.